60 results about "T-lymphocyte proliferation" patented technology

Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 ζ-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation.

Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 zeta-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation.

The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.

The invention belongs to the field of cellular immunology, and discloses a methodological study for inducing mass generation of dendritic cells (DCs) from cord blood CD34+ hematopoietic stem cells. The method comprises the following main steps: separating mononuclear cells from cord blood, separating CD34+ hematopoietic stem cells through an immunomagnetic bead positive screening method, continuously amplifying the CD34+ cells for 30 days by using an amplification culture medium (IMDM, FBS, GM-CFS, SCF), periodically collecting mass CD34-DC precursor cells during the amplification process, and inducing the precursor cells to be differentiated into immaturate DCs through a GM-CFS / IL-4 culture medium. The method disclosed by the invention is capable of obtaining the DCs with 109 orders of magnitudes; compared with the traditional DCs induced by peripheral blood mononuclear cells, the CD34-DCs have high antigen phagocytic capacity and the capacity of inducing T lymphocyte proliferation.

The invention discloses a method for promoting cell proliferation and activation of peripheral blood CD4+T lymphocyte and suppressing cell proliferation and migration of acute lymphocytic leukemia (ALL) Jurkat T cells by using red cassia tree lectin. The separation and purification of red cassia tree lectin from red cassia tree seeds can be carried out at the temperature of 1-5 DEG C during the entire process, the proliferation and activation of the peripheral blood T lymphocyte CD4 subgroup can be promoted by the red cassia tree lectin through the verifications of an MTT (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide) experiment, a DNA (deoxyribonucleic acid) analysis and an FCM (flow cytometry), and the red cassia tree lectin is CD4+T lymphocyte mitogen more efficient than PHA (Phytohaemagglutinin) and provides a new and effective way for anti-virus infection and vaccine intensifier development; through the verifications of CCK-8 (Cell Counting Kit-8) experiment, DNA analysis, cell apoptosis analysis, ELISA (enzyme-linked immuno sorbent assay) experiments and migration assay, the red cassia tree lectin can obviously suppress the proliferation and migration of the Jurkat T lymphocyte, is a growth inhibitor more efficient for the ALL cells and provides a new and effective supplementary means for treating the hematological malignancies.

The present invention discloses a CTL epitope polypeptide of porcine reproductive and respiratory syndrome virus (PRRSV) and application thereof. The amino acid sequence of the CTL epitope polypeptide of PRRSV provided by the present invention is as shown in sequence 1 in a sequence table. The invention also protects a nucleic acid molecule encoding the polypeptide. The CTL epitope polypeptide of PRRSV provided by the present invention can combine with a swine SLA-I molecule, can be used for preparing a vaccine for PRRSV and preparing a chicken CD8 + T lymphocyte proliferation agent.

The invention relates to preparation and application of a Pseudorabies virus (PRV) epitope polypeptide gene engineering vaccine. The vaccine uses PRV as the main glycoprotein, and B cell neutralizing epitope of gB, gC and gD and T cell immune epitope as the vaccine frame structure. The vaccine is prepared by the following steps: connecting the main glycoprotein with the vaccine frame structure through a flexible linker, connecting in series with a molecular adjuvant Bovine Herpesvirus 1 (BHV-1) envelope protein VP22, cloning a pRSETB vector, transforming Escherichia coli, fermenting, purifying, emulsifying and the like to obtain the PRV epitope polypeptide gene engineering vaccine. The invention also relates to an application method of the vaccine. The animal experiment indicates that the PRV epitope polypeptide gene engineering vaccine has equivalent effect to the live virus vaccine in the aspect of humoral immunity and cellular immunity level, and can be stimulated to generate T lymphopoiesis immunoreaction on the cellular level and generate antibody immunoreaction with virus neutralizing activity on the humoral level.

The invention relates to medical applications of wedelolactone and derivatives thereof, in particular to the applications in preparing medicines for treating T-cell mediated immunologic injury diseases (chronic hepatitis or autoimmune hepatitis). Traditional Chinese Medicine eclipta has a function of liver protection; wedelolactone is prepared after the active ingredient of eclipta is traced and separated, so the pharmaceutical function is proved to be produced by wedelolactone; the structure of wedelolactone is determined through the spectrum properties and physicochemical properties. Wedelolactone is provided with biological activities: high selective inhibition to ConA stimulated T lymphocyte proliferation, no inhibition to normal peripheral blood lymphocyte (NPBL), and no cytotoxicity; wedelolactone is the active ingredient of Traditional Chinese Medicine with liver protection function; the method for preparing a novel medicine from the active ingredient of eclipta, wedelolactone, has the advantages of discarding the dross and selecting the essential, clear medicinal ingredients, definite function, safety and effectiveness, controllable quality, reducing the adverse drug reaction, and can be suitable for mass production.

The present invention relates to the use of Pirlindole, if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and / or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Pirlindole and use thereof.

A new immunosuppressive agent as glycyrol has significant immunosuppressive activity, thus is useful as an immunosuppressive agent to treat relative diseases, wherein the glycyrol is a coumestrol compound extracted from glycyrrhiza, which is a small molecular compound with novel chemical structure. Tests prove that the glycyrol can inhibit the increment of T lymphocyte induced by canavaline A and inhibit one-way mixed lymphocyte reaction (MLR), release the inflammatory symptom of delayed hypersensitivity and inhibit the homologous allogenic organ transplantation rejection. The glycyrol is a high-effective low-toxicity immunosuppressive agent, with small molecular weight and simple structure, which is easy to be modified and to prepare different drug agents, therefore, the compound is a new generation immunosuppressive agent.

The invention discloses a spleen mesenchymal stem cell with an immune adjustment function, a preparation method of the cell and an application of the cell. By the aid of the strategy of removing hematopoietic cell-digestion matrix tissues to obtain Sp-MSCs-passage purification, MSCs are cultured in an isolated manner from the spleen, and a large number of Sp-MSCs with high cell purify are obtained by isolation. Further, the Sp-MSCs have high immune adjustment function, heterogenetic antigen and homologous antigen activated T lymphocyte proliferation and activation can be inhibited, and inflammatory cytokine secretion of T lymphocyte is inhibited.

Through the experiments and researches on calycosin, it has been found for the first time that calycosin can prominently inhibit the T lymphocyte proliferation induced by concanavalin A (Con A), has an immunity inhibiting effect, and is advantageously used to prepare immunity inhibitors.

The invention provides a Hyriopsis cumingii enzymolysis polypeptide, preparation and application thereof. The enzymolysis method comprises the following steps that: fresh Hyriopsis cumingii meat is crushed and pulped, and added with water of which the weight is 5 to 6 times of that of the fresh Hyriopsis cumingii meat; the mixture is boiled and filtered; the precipitate is dried and degreased to obtain albumen powder of the Hyriopsis cumingii meat; the albumen powder of the Hyriopsis cumingii meat is soaked in water of which the weight is 6 to 8 times of that of the albumen powder of the Hyriopsis cumingii meat for 11 to 12 hours and subjected to superfine grinding and even pulping, and the pH value of the mixed solution is adjusted to between 8.0 and 9.0; based on the albumen content in the albumen powder of the Hyriopsis cumingii meat, 0.3 to 0.6 percent of alkali protease is added in the mixed solution for enzymolysis for 4 to 6 hours at a temperature of between 40 and 60 DEG C; the obtained supernatant is condensed and dried to obtain the Hyriopsis cumingii enzymolysis polypeptide; and by testing, the content of the total albumen of the Hyriopsis cumingii enzymolysis polypeptide is more than or equal to 80 percent, wherein the contents of asparagic acid, glutamic acid, leucine, lysine and arginine are more than or equal to 50 percent, and the molecular weight is mainly concentrated in two zones of 6,100Da and 26,200Da. By a test for culturing mouse lymphocytes in vitro, the Hyriopsis cumingii enzymolysis polypeptide can be used for preparing a medicament for promoting proliferation of the T lymphocute and a health care food for improving the immunity.

The invention relates to a traditional Chinese medicine patch for the prevention and early-stage curing of bronchial asthma, and the treatment of a plurality of respiratory diseases and megrims, characterized in that the traditional Chinese medicine patch comprises, based on the weight percentage, 57 to 70 % of peach seed, 12 to 25 % of cape jasmine, 6 to 8 % of almond, and 5 to 10% of pepper. The invention has the advantages that the traditional Chinese medicine patch is mainly used for treating bronchial asthma, can cure the bronchial asthma of children at the age of below 12, and can be used in the outbreaking or catabatic period. The traditional Chinese medicine patch has the efficacy of diminishing inflammation, invigorating blood circulation, removing blood stasis, clearing away cold, relieving cough and calming panting. The traditional Chinese medicine patch can promote the synthesis of the alveolar surfactant, protect the pulmonary function to improve the lesion tissues, and can stimulate the proliferation of blood vessel endothelial cells to restore the endangium. The traditional Chinese medicine patch has the antiallergic effect, can inhibit the antiserum reaction of allergic antibody of the skin, reduce the pigment seepage and alleviate the airway obstruction. The traditional Chinese medicine patch can enhance the proliferation and conversion of T lymphocyte of spleen of a body, and improve the autoimmunity.

The invention discloses a lactic acid bacteria extracellular polysaccharide and an immune adjuvant. The Lactobacillus casei (Lactobacillus casei) WXD030 protected by the present invention is depositedunder the accession number CGMCC No. 12415. The Lactobacillus casei WXD030 is deposited under the accession number CGMCC No. 12415. Extracellular polysaccharide can significantly enhance the secretion of cytokines from bone marrow-derived dendritic cells in mice. Immunization of mice with exopolysaccharide and OVA antigen could significantly increase the titers of IgG antibody and IgG subclass specific for OVA in mice serum, while immunization of mice with exopolysaccharide and OVA antigen could increase the titers of IgG antibody subclass specific for OVA in mice serum. Extracellular polysaccharides could also significantly promote splenic T lymphocyte proliferation and INF-Gamma and IL-4 secretion; Significant increase in spleen IL-4 + CD4 + T cells, IFN-Gamma + CD4 + T cells and IFN-Gamma + CD8 + T cells; In addition, extracellular polysaccharide could significantly enhance the titer of specific antibody induced by inactivated FMD vaccine in mice.

Through the researches and experiments on astraisoflavan-7-O-beta-D-glucoside, it has been found for the first time that astraisoflavan-7-O-beta-D-glucoside can prominently inhibit T lymphocyte proliferation induced by concanavalin A (Con A) and rat isolated arterial ring contracts induced by potassium chloride (KCl), has immunity inhibiting and vasodilative effects, and is advantageously used to prepare immunity inhibitors and vasodilators.

The invention relates to recombinant bacillus subtilis capable of synthesizing carotenoid 4,4'-diaponeurosporene with 30 carbon atoms (C30), and belongs to the biotechnology genetic engineering field. A bacillus subtilis expression plasmid pMK3-crtmn (which is capable of expressing C30 carotenoid synthases Crtm and Crtn in bacillus subtilis) containing C30 carotenoid synthase genes crtm and crtn is successfully constructed, and is successfully electro-transformed into bacillus subtilis WB800. The WB800 strain after transformation turns from the original color of white to yellow. A pigment component extracted from the recombinant WB800 is identified as 4,4'-diaponeurosporene by high performance liquid chromatography (HPLC). 4,4'-diaponeurosporene can stimulate maturation of dendritic cells, and generated cytokines (IL-6, IL-10, IL-12p70 and TNF[alpha]) have the amount increased, and moreover and have stronger ability to stimulate proliferation of T lymphocytes. With oral administration of the bacillus subtilis capable of synthesizing 4,4'-diaponeurosporene, the dextran sulphate sodium (DSS)-induced mice colitis symptoms can be significantly reduced. The bacillus subtilis capable of producing 4,4'-diaponeurosporene is expected to be developed as probiotics for prevention of colitis.

Through the experiments and researches on calycosin-7-glucoside, it has been found for the first time that calycosin-7-glucoside can prominently inhibit the T lymphocyte proliferation induced by concanavalin A (Con A) and reduce the macrophage toxicity induced by lipopolysaccharide (LPS), has immunity inhibiting and anti-inflammatory effects, and is advantageously used to prepare immunity inhibitors and anti-inflammatory drugs.

The invention relates to preparation and application of an infectious bursal disease (IBD) protein engineering vaccine. The preparation method comprises the following steps: connecting B cell neutralizing epitope and T cell immunizing epitope of IBDV (infectious bursal disease virus) primary structure proteins VP2 and VP3 as a vaccine frame structure through a flexible linker, connecting with cell factor poultry interleukin 15(chIL-15) in series, cloning into a pRSETB vector, transforming Escherichia coli, fermenting, purifying, emulsifying and the like to obtain the IBD protein engineering vaccine with ideal immunogenicity. The invention also relates to an application method of the vaccine. The animal experiment indicates that the IBD protein engineering vaccine has equivalent effects to the live virus vaccine on the humoral immunity and cellular immunity level, and can stimulate the generation of T lymphopoiesis immunoreaction on the cellular level and the generation of antibody immunoreaction with virus neutralizing activity on the humoral level. The attacking protection test indicates that the IBD protein engineering vaccine group has obviously better effects than the live vaccine group.

Through the experiments and researches on astrapterocarpan, it has been found for the first time that astrapterocarpan can prominently inhibit the T lymphocyte proliferation induced by concanavalin A (Con A), has an immunity inhibiting effect, and thus can be advantageously used to prepare immunity inhibiting drug.

The present invention relates to the technical field of biology, specifically to induced culture and purification of human suppressive b-lymphocytes and applications of a potential cell therapy method in autoimmune diseases. According to the method, human peripheral blood is sterilely sampled, LymphoprepTM (Axis-Shield) is adopted to separate human mononuclearcell, the separated cell is placed in a 10% FBS-containing RPMI1640 culture medium to culture, and concurrently 50 ng / ml of human recombinant BAFF cytokine is added at a first day, a third day and a fifth day to induce suppressive b-lymphocyte production. According to the present invention, the BAFF is adopted for differentiation of the human peripheral blood B cells into the suppressive b-lymphocytes through in vitro induction, wherein the suppressive b-lymphocytes express IL-10, and have T lymphocyte proliferation inhibition capability.

The invention provides a separated biological membrane as well as a preparation method and application of the separated biological membrane. The invention further provides a method and an application of the biological membrane for stimulating T lymph cell proliferation; and furthermore, the invention provides a kit containing the biological membrane.

The invention discloses the function of CH25H (cholesterol-25-hydroxylase) and 25-OHC in immune response and application thereof as an immunomodulator in vaccines. The invention finds that 25-OHC can significantly inhibit inflammation immunologic reaction, can inhibit immune cell overexpressed IL-1b and TNF-a, and has very important application value for adjustment of virus infection patient persistent immune activation and inflammatory reaction. Without affecting antigen specific T lymphocyte proliferation, 25-OHC strongly inhibits mitogen stimulated lymphocyte overproliferation effect. 25-OHC can be used as the immunomodulator of a HIV (human immunodeficiency virus) vaccine to improve the immune effect of the vaccine, and can be widely applied to prevention and treatment of AIDS. The mentioned immunomodulatory effect is in favor of designing a new generation of HIV vaccine, i.e. reducing CD4<+> T cell immune response to the greatest extent without affecting body protective CD8<+> T cell immune functions.

The invention belongs to the fields of medicine and bioengineering, and discloses an immunoregulation peptide, and a preparation method and application thereof. The amino acid sequence of the immunoregulation is disclosed as SEQ ID NO:1. The immunoregulation peptide has high T lymphopoiesis promoting function, and can be used for preparing T lymphopoiesis promoting drugs.

The invention provides application of Pu'er tea and Pu'er tea preparation in preventing and treating plague, namely the Pu'er tea and the Pu'er tea preparation can inhibit the activity of protein tyrosine phosphatase of Yersinia outer membrane protein H - YopH in vitro. The outer membrane protein H in Yersinia is an only protein with the activity of the protein tyrosine phosphatase, can perform dephosphorylation on certain proteins of eukaryotic cells, not only damages the cytoskeleton and has antiphagocytic function but also can inhibit PI-3 channels so as to inhibit T lymphopoiesis, and is an important factor for the Yersinia to escape innate immunological response of hosts. Therefore, diseases caused by the Yersinia can be prevented and treated by inhibiting the activity of the protein tyrosine phosphatase of the Yersinia outer membrane protein H - the YopH, and a Pu'er tea effective inhibitor sieved by taking the Yersinia outer membrane protein H - the YopH as a target provides a novel method and novel concept for prevention and treatment of plague.

The invention obtains neodicoumarin compound that is 1,3-(6',6'',7',7''-tetramethoxy-8', 8''-dicoumarin)-acetone with immunologic suppression effect, in particular with induced specific immunologic tolerance effect that is extracted and separated from Honghuoma acetic ether extract, wherein the compound produces induced specific immunologic tolerance or achieve new balance effect for unbalanced immune system by inhibiting the multiplication of T lymphocyte, reducing the expression of intracellular transcription factor T-bet of dendritic cell (DC), inducing immature DC and adding the amount of T cells expressing Foxp3 regulation and can be used as an immunosuppressive agent, thereby being used for the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The invention relates to the field of medicine and pharmacology and discloses application of 2H-1-chromene-2-ketone in medicine preparation. By the experimental researches of the 2H-1-chromene-2-ketone, the facts that the 2H-1-chromene-2-ketone can evidently resist T lymphocyte proliferation induced by concanavalin A (ConA), B lymphocyte proliferation induced by lipopolysaccharide (LPS) and macrophage toxicity, can lower the expression of LPS-induced B lymphocyte surface B-cell activating factor receptor (BAFF-R) CD268 and lower the expression of marrow source DC cells and the expression of LPS-induced primary DC cell surface costimulatory molecules CD86, and has immunosuppressive action and anti-inflammatory action are discovered for the first time. Meanwhile, the 2H-1-chromene-2-ketone has evident inhibiting effects on the proliferation of various cancer cell lines and is applicable to the preparation of immunosuppressant and anti-inflammatory and anti-cancer medicine.

The invention discloses a cell culture medium. The cell culture medium is prepared from components as follows: 80v / v%-90v / v% of a DMEM / F12 culture medium, 25-500 mg / ml of a sericin solution, 2.0-5 mg / ml of a chitosan quaternary ammonium salt solution, 35-70 mg / ml of human serum albumin, 20-80 mg / ml of phytohemagglutinin, 20-100 mu g / ml of vitamin C, 20-80 mu g / ml of vitamin E, 0.5-10 ng / ml of an epidermal growth factor, 5-20 ng / ml of an insulin-like growth factor and 1-5 mmol / ml of L-glutamine. Cell growth can be promoted by use of sericin, and the chitosan quaternary ammonium salt solution isused for the cell culture medium, can improve the cell proliferation capability and tumor killing rate and can improve the cell growth capability when matched with sericin for use. Kidney bean lectinhas the functions of agglutinating blood cells, lymphocyte, spermatid and the like, and in in-vitro cell culture, phytolectin can proliferate lymphocyte; in the whole experiment, the phytolectin canimprove the immune capability of a body; under the synergistic action of sericin, the chitosan quaternary ammonium salt solution and lectin, the proliferation rate, the survival rate and the tumor killing rate of T lymphocyte are remarkably increased.

The invention discloses a kit used for identifying hematopoietic stem cell transplantation effect. The kit comprises assemblies A, B, C, D, E, F, G, and H. The assembly A is a substance used for preparing bone marrow mononuclear cells; the assembly B is a substance used for culturing bone marrow mesenchymal stem cells to form colonies; the assembly C is a substance used for counting the bone marrow mesenchymal stem cell colonies; the assembly D is a substance used for identifying whether bone marrow mesenchymal stem cells are capable of being differentiated into osteoblasts; the assembly E is a substance used for identifying whether bone marrow mesenchymal stem cells are capable of being differentiated into adipocytes; the assembly F is a substance used for identifying whether bone marrow mesenchymal stem cells have capacity of inhibiting T lymphocyte proliferation; and the assembly G is a substance used for identifying whether bone marrow mesenchymal stem cells are capable of being feeder cells of hematopoietic stem cells. The kit provided by the invention is convenient and practical, and is simple to operate. The kit can be used for detecting bone marrow hematopoietic microenvironment recovery condition after a hematopoietic stem cell transplantation operation. With the kit, a basis is provided for the researched on mesenchymal stem cells.

The invention relates to the field of natural medicines, in particular to the medical application of garden balsam seed, i.e. the medical application of garden balsam seed for preventing rheumatoid arthritis. The pharmacological test shows that the garden balsam seed saponin has good application of preventing the rheumatoid arthritis. When the concentration is 30 mu mole / L, the garden balsam seed saponin can obviously restrain T lymphopoiesis induced by concanavalin A.